Adult intracranial WHO grade II ependymomas: Long-term outcome and prognostic factor analysis in a series of 114 patients

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 976-984

  Metellus, Philippe ^a   Guyotat, Jacques ^d   Chinot, Olivier ^b   Durand, Anne ^a,c   Barrie, Marylin ^b   Giorgi, Roch ^d   Jouvet, Anne ^d   Figarella Branger, Dominique ^a  

^a Department of Neurosurgery ^*  (France)

^b Neuro oncological Unit   (France)

^c TIMONE HOSPITAL   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Adults; Ependymomas; Histology; Prognostic factors; Radiotherapy

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; EPENDYMOMA; FEMALE; FOLLOW UP; HUMAN; INTRACRANIAL EPENDYMOMA; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPENDYMOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PROGNOSIS; RADIOTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650140985     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq047     Document Type: Article

References (25)

1. Reni M, Brandes AA, Vavassori V, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer. 2004;100:1221-1229.
2. Rawlings CE III, Giangaspero F, Burger PC, Bullard DE. Ependymomas: a clinicopathologic study. Surg Neurol. 1988;29:271-281.
3. Guyotat J, Signorelli F, Desme S, et al. Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol. 2002;60:255-268.
4. Ernestus RI, Schroder R, Stutzer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg. 1997;11:421-428.
5. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer. 2004;100:1230-1237.
6. Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain. 2007;130:1338-1349.
7. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg. 2000;93: 605-613.
8. Kurt E, Zheng PP, HopWC, et al. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer. 2006;106:388-395.
9. McLaughlin MP, Marcus RB, Jr, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys. 1998;40:845-850.
10. Paulino AC, Wen BC, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol. 2002;25:117-122.
11. Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas?J Neurosurg. 2005;102:629-636.
12. Schild SE, Nisi K, Scheithauer BW, et al. The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1998;42:953-958.
13. Rodriguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res. 2009;156:340-351.
14. Bouvier C, Bartoli C, Aguirre-Cruz L, et al. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg. 2003;99:344-350.
15. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N. Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg. 2005;103:31-37. (Pubitemid 43193931)
16. Paulino AC, Wen BC. The significance of radiotherapy treatment duration in intracranial ependymoma. Int J Radiat Oncol Biol Phys. 2000;47:585-589.
17. Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol. 2002;56: 87-94.
18. Vanuytsel LJ, Bessell EM, Ashley SE, Bloom HJ, Brada M. Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:313-319.
19. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. 1998;88:695-703.
20. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol. 1997;7:807-822.
21. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol. 2003;163:1721-1727.
22. Palm T, Figarella-Branger D, Chapon F, et al. Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer. 2009;115:3955-3968.
23. Stuben G, Stuschke M, Kroll M, Havers W, Sack H. Postoperative radiotherapy of spinal and intracranial ependymomas: analysis of prognostic factors. Radiother Oncol. 1997;45:3-10.
24. Spagnoli D, Tomei G, Ceccarelli G, et al. Combined treatment of fourth ventricle ependymomas: report of 26 cases. Surg Neurol. 2000;54:19-26. discussion.
25. Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys. 2005;61:387-391.